{"id":57580,"date":"2025-12-22T14:58:31","date_gmt":"2025-12-22T14:58:31","guid":{"rendered":"https:\/\/prosfunds.com\/?p=57580"},"modified":"2025-12-22T14:58:31","modified_gmt":"2025-12-22T14:58:31","slug":"cytokinetics-incorporated-cytk-discusses-fda-approval-of-myqorzo-for-symptomatic-obstructive-hypertrophic-cardiomyopathy-transcript","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=57580","title":{"rendered":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript"},"content":{"rendered":"
\n

Company Participants<\/strong><\/p>\n

Diane Weiser – Senior Vice President of Corporate Affairs<\/span>
Robert I. Blum – CEO, President & Director<\/span>
Fady Malik – Executive Vice President of Research & Development<\/span>
Andrew Callos – Executive VP & Chief Commercial Officer<\/span><\/p>\n<\/p><\/div>\n

\n

Conference Call Participants<\/strong><\/p>\n

Zaki Molvi – Jefferies LLC, Research Division<\/span>
Tessa Romero – JPMorgan Chase & Co, Research Division<\/span>
Roanna Clarissa Ruiz – Leerink Partners LLC, Research Division<\/span>
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division<\/span>
Salim Syed – Mizuho Securities USA LLC, Research Division<\/span>
Mario Joshua Chazaro Cortes – Evercore ISI Institutional Equities, Research Division<\/span>
Jason Butler – Citizens JMP Securities, LLC, Research Division<\/span>
Srikripa Devarakonda – Truist Securities, Inc., Research Division<\/span>
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division<\/span>
Martin Auster – Raymond James & Associates, Inc., Research Division<\/span>
Yasmeen Rahimi – Piper Sandler & Co., Research Division<\/span>
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division<\/span>
Serge Belanger – Needham & Company, LLC, Research Division<\/span>
Maxwell Skor – Morgan Stanley, Research Division<\/span>
Leonid Timashev – RBC Capital Markets, Research Division<\/span>
Mayank Mamtani – B. Riley Securities, Inc., Research Division<\/span>
Ashwani Verma – UBS Investment Bank, Research Division<\/span>
Jason Zemansky – BofA Securities, Research Division<\/span><\/p>\n<\/p><\/div>\n

\n

Presentation<\/strong><\/p>\n

\n

Operator<\/strong><\/span><\/p>\n

Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to Cytokinetics conference call for the FDA approval of MYQORZO. [Operator Instructions]. <\/p>\n

At this time, I would like to turn the call over to Diane Weiser, Cytokinetics’ Senior Vice President of Corporate Affairs. Please go ahead.<\/p>\n<\/p><\/div>\n

\n

Diane Weiser<\/strong><\/span>
Senior Vice President of Corporate Affairs<\/i><\/span><\/p>\n

Good afternoon, and thanks for joining us on today’s call to discuss the FDA approval of MYQORZO for symptomatic obstructive HCM. Today, I’m joined by my colleagues, Robert Blum, President and CEO, who will provide introductory<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Company Participants Diane Weiser – Senior Vice President of Corporate AffairsRobert I. Blum – CEO, President & DirectorFady Malik – Executive Vice President of Research & DevelopmentAndrew Callos – Executive VP & Chief Commercial Officer Conference Call Participants Zaki Molvi – Jefferies LLC, Research DivisionTessa Romero – JPMorgan Chase & Co, Research DivisionRoanna Clarissa Ruiz […]<\/p>\n","protected":false},"author":1,"featured_media":3613,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[38],"tags":[],"class_list":{"0":"post-57580","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news"},"yoast_head":"\nCytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds<\/title>\n<meta name=\"description\" content=\"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=57580\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=57580\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T14:58:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=57580#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57580\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript\",\"datePublished\":\"2025-12-22T14:58:31+00:00\",\"dateModified\":\"2025-12-22T14:58:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57580\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=57580#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=57580\",\"url\":\"https:\/\/prosfunds.com\/?p=57580\",\"name\":\"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2025-12-22T14:58:31+00:00\",\"dateModified\":\"2025-12-22T14:58:31+00:00\",\"description\":\"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57580#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=57580\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=57580#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds","description":"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=57580","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds","og_description":"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice","og_url":"https:\/\/prosfunds.com\/?p=57580","og_site_name":"Prosfunds","article_published_time":"2025-12-22T14:58:31+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=57580#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=57580"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript","datePublished":"2025-12-22T14:58:31+00:00","dateModified":"2025-12-22T14:58:31+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=57580"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=57580#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=57580","url":"https:\/\/prosfunds.com\/?p=57580","name":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2025-12-22T14:58:31+00:00","dateModified":"2025-12-22T14:58:31+00:00","description":"Company Participants Diane Weiser - Senior Vice President of Corporate AffairsRobert I. Blum - CEO, President & DirectorFady Malik - Executive Vice","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=57580#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=57580"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=57580#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57580"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57580\/revisions"}],"predecessor-version":[{"id":57581,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57580\/revisions\/57581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/3613"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}